Published: 18 September 2022
Author(s): Isaac Núñez, Yanink Caro-Vega, Adrian Soto-Mota
Issue: January 2023
Section: Letter to the Editor

Numerous unproven therapies for coronavirus disease 2019 (COVID-19) were adopted early on based on inadequate evidence [1]. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) is a large simple trial designed to quickly evaluate treatments for hospitalised patients [2]. RECOVERY reported increased survival with dexamethasone, particularly among patients that required supplemental oxygen [2]. Patients with invasive mechanical ventilation (IMV) at randomization who received dexamethasone had a 28-day rate ratio (RR) for mortality of 0.64 (95%CI, 0.51–0.81), while those receiving supplementary oxygen with a non-invasive device had a RR of 0.82 (95%CI, 0.72–0.94).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.